HeartX’s accelerator program facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations, according to an Oct. 16 news release.
Here are the five cardiovascular inventions chosen for the 2023 program:
Flosonics Medical (Canada): Flosonics produces a wireless wearable ultrasound device that assesses carotid arterial pulse within seconds. The data is designed to help physicians determine when a patient is no longer fluid-responsive.
Happitech (The Netherlands): Happitech offers a solution to identify patients at risk for atrial fibrillation. It allows individuals to place a finger on a smartphone’s camera for 90 seconds to screen for the condition.
MindMics (Massachusetts): MindMics offers heart monitoring technology through low-frequency acoustical vibrations detected in the ear canal with technology embedded in earbuds and hearing aids.
Nanowear (New York): Nanowear is an AI-based remote diagnostics tool utilizing cloth-based nanotechnology that allows nanosensors to capture more than 85 medical-grade biomarkers directly from the skin.
SmartCardia (Switzerland): SmartCardia produces a patch that remotely monitors patients, allowing mobile cardiac telemetry, RPM, Holter, extended Holter and event monitoring.
Each company will receive $150,000 investment and access to clinicians and administrators while executing their pilot projects and clinical studies in the HeartX program.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.